Chemomab Therapeutics Ltd. announced that Adi Mor, PhD, co-Founder and former Chief Executive Officer (CEO) of Chemomab, and current Director and Chief Scientific Officer, has been reappointed to the role of CEO, replacing Dale Pfost, PhD. All the appointments were effective June 1, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.68 USD | +6.27% | +3.05% | +33.33% |
Apr. 10 | Transcript : Chemomab Therapeutics Ltd. - Special Call | |
Mar. 07 | Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.33% | 9.09M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- CMMB Stock
- News Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Ltd. Names Adi Mor, Phd as CEO